Formulation Sample Clauses

Formulation. The formulation of BL-1040 is shown in Table 5.1.

Formulation. The Annual Performance Bonus will be determined from Employer's earnings before state and federal taxes ("Before Tax Earnings"). The Board shall each year during the term of this Agreement establish a Performance Bonus Criteria (herein so called) which shall be Employer's budgeted Before Tax Earnings for that year and which shall not be less than the Performance Bonus Criteria for the immediately preceding year. (a) If Before Tax Earnings are less than 80% of Performance Bonus Criteria, Employee shall earn no Annual Performance Bonus. If Before Tax Earnings are equal to at least 80% of the Performance Bonus Criteria, Employee shall earn an 6 Annual Performance Bonus as determined under Paragraphs 5(B)(1)(b), (c) and (d) below, as applicable. (b) If Before Tax Earnings are 80%-99% of the Performance Criteria, Employee shall earn an Annual Performance Bonus in an amount ranging between 25% and 48.75 % of Employee's Base Salary, determined on a prorated basis. For example, if Before Tax Earnings are 92% of the Performance Bonus Criteria, Employee shall earn an Annual Performance Bonus equal to 40% of Employee's Base Salary. (c) If Before Tax Earnings are 100%-119% of the Performance Criteria, Employee shall earn an Annual Performance Bonus in an amount ranging between 50% and 97.5% of Employee's Base Salary, determined on a prorated basis. For example, if Before Tax Earnings are 110% of the Performance Criteria, Employee shall earn an Annual Performance Bonus equal to 75% of Employee's Base Salary. (d) If Before Tax Earnings are 120% or greater of the Performance Bonus Criteria, Employee shall earn an Annual Performance Bonus equal to 100% of Employee's Base Salary, plus an additional 2% of Employee's Base Salary for each 1% above 120% of the Performance Bonus Criteria.

Formulation. Genentech and/or its sublicensee(s) shall be responsible for formulating such Lead Products and shall bear all associated costs.

Formulation. Renovis and/or its sublicensee(s) shall be responsible for formulating such Renovis Products and shall bear all associated costs.

Formulation. The term "Formulation" is defined in Section 3.01(i) below.

Formulation. Genentech and/or its Affiliates or sublicensee(s) shall be responsible for formulating such Genentech Products and shall bear all associated costs.

Formulation. Xxxxxx experienced significant difficulty verbalising the nature of her intrusions, which resulted from her strong belief in moral and likelihood TAF. This was compounded by guilt, shame and embarrassment, which she experienced due to the nature of her intrusive images. Consequently three sessions were required to formulate and aid engagement. This led to three CBT formulations, which were developed collaboratively with Xxxxxx and referred to throughout treatment.

Formulation. PURCHASER agrees that any batch of Wyeth Product that contains DHA Martek Product or XXX Xxxxxx Product shall not contain DHA or ARA obtained from any Third Party and that Martek Product shall comprise one hundred percent (100%) of any and all DHA and ARA contained in such batch of Wyeth Product.

Formulation. AstraZeneca will be responsible for conducting and paying for all formulation work to conduct the Amendment-Additional Collaboration Target Program. If requested by AstraZeneca, during the Amendment-Additional Collaboration Term Isis will provide reasonable assistance to AstraZeneca for such work as set out in the Amendment-Additional Collaboration Target Research and Development Plan. Isis will provide such assistance on an hourly basis [***] up to a reasonable maximum number of hours set by the Amendment-Additional Collaboration Target Working Group for each year of the Amendment-Additional Collaboration Term, and thereafter at Isis’ then current FTE Rate. AstraZeneca will resupply any finished Product necessary to support any Isis Conducted Activities, AstraZeneca Conducted Activities, IND toxicology studies and the Phase 1 Study for the Amendment-Additional Collaboration Target Program.

Formulation. 2.1.2.2.3.1 Sarepta shall generate internally, the development of a formulation method of the API, AVI-7288, [†††] Decision: [†††]